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A Ab bs st tr ra ac ct t
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominantly inherited disorder, characterised by
the occurrence of tumours of the parathyroid glands, the pancreatic islets, the pituitary gland, the adrenal glands
and neuroendocrine carcinoid tumours. Carcinoid tumours of the thymus and pancreatic-duodenal gastrinomas
are the most harmful tumour types, since these tumours have malignant potential and curative treatment is
difficult to achieve. 
MEN1 is caused by germline mutations of the MEN1 tumour suppressor gene. Mutation analysis enables mutation
carriers to be identified. MEN1 patients and their family members, family members of mutation carriers and
patients who are clinically suspected to be carriers of a MEN1 gene mutation are eligible for mutation analysis. 
MEN1-associated tumours can be detected and treated at an early stage through periodical clinical monitoring
of mutation carriers. 
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I In nt tr ro od du uc ct ti io on n
Multiple endocrine neoplasia type 1 (MEN1) is 
an autosomal dominantly inherited syndrome. MEN1
is characterised by the occurrence of tumours of the
parathyroid glands, the pancreatic islets, the anterior
pituitary gland and the adrenal glands, as well as
neuroendocrine carcinoid tumours, often at a young
age. Non-endocrine manifestations of MEN1 include
angiofibromas,  collagenomas,  lipomas  and
leiomyomas (Table 1). The prevalence of MEN1 is 2-3
per 100,000, and is equal among males and females. 
MEN1 and multiple endocrine neoplasia type
2 (MEN2) are two distinct syndromes. In MEN2,
patients  frequently  develop  medullary  thyroid
carcinoma and pheochromocytoma. 
MEN1 is caused by germline mutations of the
MEN1 gene [1, 2]. Since the discovery of the gene in
1997,  mutation  analysis  has  become  available.
Carriers of a MEN1 gene germline mutation can be
monitored periodically to identify MEN1-associated
lesions at a presymptomatic stage. 
In this report, we give an overview of the recent
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well as the current diagnostic and therapeutic options.
Furthermore, we provide guidelines for MEN1 mutation
analysis and periodical clinical monitoring. 
C Cl li in ni ic ca al l   m ma an ni if fe es st ta at ti io on ns s, ,   d di ia ag gn no os si is s   
a an nd d   t tr re ea at tm me en nt t
The clinical definition of a MEN1 patient we use is
a patient with three or more of the five major MEN1-
associated lesions (i.e. tumours of the parathyroid glands,
the endocrine pancreas, the pituitary gland, the adrenal
glands, and neuroendocrine carcinoid tumours). 
A suspected MEN1 patient is defined as having
two major MEN1-associated lesions, multiple lesions
within one organ, and/or a lesion at a young age
(<35 years) [3]. 
Below, for each tumour type the clinical presentation
and the diagnostic and therapeutic options are listed.
In Figure 1, flow charts are shown for diagnosis and
therapy of MEN1-associated parathyroid adenoma,
tumours of the pancreatic islets and pituitary adenoma. 
P Pa ar ra at th hy yr ro oi id d   a ad de en no om ma a
Parathyroid adenomas (Fig. 1A) are often the first
manifestation of MEN1. 75-95% of MEN1 patients
develop parathyroid adenomas [4, 5]. The increased
production  of  parathyroid  hormone  causes
hypercalcaemia. Fatigue, depression, constipation,
nausea,  symptoms  caused  by  nephrolithiasis  or
nephrocalcinosis, bone pain, myalgia and arthralgia
as well as hypertension may all be signs and symptoms
of hypercalcaemia. 
Laboratory investigation consists of measurement of
ionised calcium, chloride, phosphate and parathyroid
hormone. In addition to this, the 24-hour calcium
excretion in the urine is measured. Bone densitometry
can be used to detect bone mass reduction. 
Van Dalen et al showed that parathyroid adenomas
can be effectively localised by ultrasound, supplemented
with computed tomography (CT) [6]. Alternatively,
a scan can be made with Tc-99m sestamibi that is
retained selectively by parathyroid adenomas. 
Usually,  parathyroid  adenomas  in  MEN1  are
benign. When a tumour causes hypercalcaemia, it is
surgically removed, preferably in a minimally invasive
procedure. If this is not possible, a conventional neck
exploration can be performed [7]. 
T Tu um mo ou ur rs s   o of f   t th he e   e en nd do oc cr ri in ne e   p pa an nc cr re ea as s
Tumours  of  the  endocrine  pancreas  (Fig.  1B)
develop  in  about  70%  of  MEN1  patients  [8].
Gastrinomas are the most common pancreatic tumour
in MEN1. The elevated levels of gastrin cause excessive
gastric acid production. If untreated, this can lead to
the Zollinger-Ellison syndrome: ulcerations of the
digestive tract, diarrhoea, and mucosal hypertrophy.
Before treatment with proton pump inhibitors became
available, the Zollinger-Ellison syndrome was a frequent
cause of death of MEN1 patients. Gastrinomas are still
an important threat to MEN1 patients, because they
are often multicentric and are able to metastasise to
the lymph nodes and the liver [9]. 
Insulinomas and glucagonomas affect blood glucose
levels. Besides, glucagonomas can cause skin lesions.
Tumours producing vasoactive intestinal peptide (VIP),
VIPomas, can cause the Verner-Morrison syndrome, or
watery-diarrhoea-hypokalemia-achlorhydria (WDHA)
T Ta ab bl le e   1 1. .   T Th he e   v va ar ri ia ab bl le e   e ex xp pr re es ss si io on n   o of f   M ME EN N1 1. .   P Pe er rc ce en nt ta ag ge es s   o of f   M ME EN N1 1
g ge er rm ml li in ne e   m mu ut ta at ti io on n   c ca ar rr ri ie er rs s   t th ha at t   d de ev ve el lo op p   a a M ME EN N1 1- -a as ss so oc ci ia at te ed d   t tu um mo ou ur r. .
A AC CT TH H: :   a ad dr re en no oc co or rt ti ic co ot tr ro op ph hi ic c   h ho or rm mo on ne e
Parathyroid adenomas 75-95%
Pancreatic islet cell tumours 70%
Gastrinomas 45%
Insulinomas 10%
Non-functioning 10% 
(including pancreatic polypeptide producing tumours) 
Other 2%
Pituitary adenomas 47%
Prolactinomas 30%
Non-functioning 10%
(i.e. not producing hormone) 
ACTH producing 1%
GH producing 3-6%
Adrenal adenomas 20%
Carcinoid tumours 18%
Thymus 8%
Bronchial 8%
Stomach 5%
Skin lesions 80%
Angiofibromas 75%
Collagenomas 5%
Lipomas 30%
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F Fi ig g. .   1 1. .   R Re ec co om mm me en nd da at ti io on ns s   f fo or r   d di ia ag gn no os si is s   a an nd d   m ma an na ag ge em me en nt t   o of f   p pa ar ra at th hy yr ro oi id d   a ad de en no om ma as s   ( (A A) ), ,   p pa an nc cr re ea at ti ic c   i is sl le et t   c ce el ll l   t tu um mo ou ur rs s   ( (B B) ), ,   a an nd d   p pi it tu ui it ta ar ry y
a ad de en no om ma as s   ( (C C) )   i in n   M ME EN N1 1   p pa at ti ie en nt ts s. .   
P PT TH H: :   p pa ar ra at th hy yr ro oi id d   h ho or rm mo on ne e; ;   C CT T: :   c co om mp pu ut te ed d   t to om mo og gr ra ap ph hy y; ;   Z ZE ES S: :   Z Zo ol ll li in ng ge er r- -E El ll li is so on n   s sy yn nd dr ro om me e; ;   W WD DH HA A: :   w wa at te er ry y   d di ia ar rr rh ho oe ea a, ,   h hy yp po ok ka al le em mi ia a, ,   a ac ch hl lo or rh hy yd dr ri ia a; ;   V VI IP P: :   v va as so oa ac ct ti iv ve e
i in nt te es st ti in na al l   p pe ep pt ti id de e; ;   N NF FT T: :   n no on n- -f fu un nc ct ti io on ni in ng g   t tu um mo ou ur r; ;   P PR RL L: :   p pr ro ol la ac ct ti in n; ;   G GH H: :   g gr ro ow wt th h   h ho or rm mo on ne e; ;   A AC CT TH H: :   a ad dr re en no oc co or rt ti ic co ot tr ro op ph hi ic c   h ho or rm mo on ne e; ;   S SA A: :   s so om ma at to os st ta at ti in n   a an na al lo og gu ue es s
F Fi ig g. .   2 2. .   ( (A A) )   C CT T   i im ma ag gi in ng g   o of f   a a 4 42 2- -y ye ea ar r- -o ol ld d   M ME EN N1 1   p pa at ti ie en nt t. .   A A l le es si io on n   i is s   p pr re es se en nt t   i in n   t th he e   m me ed di ia as st ti in nu um m   ( (i in nd di ic ca at te ed d   w wi it th h   g gr re ee en n   a ar rr ro ow ws s) ). .   T Th he e   l le es si io on n
t tu ur rn ne ed d   o ou ut t   t to o   b be e   a a c ca ar rc ci in no oi id d   t tu um mo ou ur r   o of f   t th he e   t th hy ym mu us s. .   D Du ue e   t to o   i in nv va as si iv ve e   g gr ro ow wt th h   i in nt to o   t th he e   p pl le eu ur ra a   t th he e   t tu um mo ou ur r   c co ou ul ld d   n no ot t   b be e   c co om mp pl le et te el ly y   r re em mo ov ve ed d. .
( (B B) )   C Ch he es st t   C CT T   o of f   t th he e   s sa am me e   p pa at ti ie en nt t, ,   f fi iv ve e   y ye ea ar rs s   l la at te er r. .   T Th he e   t tu um mo ou ur r   i in n   t th he e   u up pp pe er r   m me ed di ia as st ti in nu um m   h ha as s   e ex xp pa an nd de ed d; ;   t th he er re e   i is s   c co om mp pr re es ss si io on n   o of f   t th he e   t tr ra ac ch he ea a. .
T Th he e   p pa at ti ie en nt t   d di ie ed d   f fr ro om m   r re es sp pi ir ra at to or ry y   f fa ai il lu ur re e
P Pa ar ra at th hy yr ro oi id d   a ad de en no om ma as s
– Multicentric
– Benign
A A B B C C
P Pa an nc cr re ea at ti ic c   i is sl le et t   c ce el ll l   t tu um mo ou ur rs s
– Multicentric
– Potentially malignant
P Pi it tu ui it ta ar ry y   a ad de en no om ma as s
– Multicentric
– Benign
Biochemical 
screening
Biochemical 
screening
Biochemical screening
Hormonal 
syndromes
Hormonal 
syndromes
– ZES
– Hypoglyceamia
– Glucagonoma
– WDHA (VIP) Hormonal syndrome:
hyperparathyroidism 
(if functional)
Imaging:
– ultrasound
– CT scan
– 99Tc sestamibi scan
Peroperatively:
PTH, sestamibi,
venous sampling
Minimally
invasive
Neck exploration
Tumour not
localised
Tumour 
localised
24-hour urine calcium
Creatinin clearance
Bone densitometry
Surgery:
– preoperatively:
gastroduodenoscopy, 
endoscopic ultrasound
– preoperatively:
palpation, 
intraoperative ultrasound
– based on outcome:
enucleation, 
distal pancreatectomy,
duodenotomy (gastrinomas),
lymphadenectomy (gastrinomas)
Tumours <3 cm
– encapsulated
– non invasive
Expectative
Tumour progression
and/or >3 cm
Dopamine
agonists
Macroadenoma
(>10 mm)
Visual field defects
Imaging Imaging
NFT
SA
Transsphenoidal surgery
PRL      GH       ACTH
A A
B B
* ** *   T Tr ra ac ch he ea a
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syndrome. Laboratory investigation includes glucose,
insulin, c-peptide, glucagon, gastrin, and pancreatic
polypeptide.  Pancreatic  islet  cell  tumours  can  be
visualised  by  magnetic  resonance  imaging  (MRI),
somatostatin receptor scintigraphy (SRS), or CT. Surgery
is required when the tumour is causing a functional
syndrome. If a gastrinoma is larger than 3 cm in
diameter and/or is progressively expanding, the tumour
and the peripancreatic lymph nodes should be resected
and a duodenotomy should be carried out to assess the
presence of duodenal tumours [8]. Surgical excision of
glucagonomas, insulinomas and VIPomas is usually
curative. Tumours producing pancreatic polypeptide are
common, but only rarely cause symptoms and therefore
do normally not require treatment. 
P Pi it tu ui it ta ar ry y   a ad de en no om ma as s
The most frequently occurring pituitary tumours in
MEN1 are prolactinomas (Fig. 1C). Non-functioning
tumours, growth hormone, or adrenocorticotrophic
hormone  (ACTH)  producing  tumours  and  mixed
tumours are seen less frequently. Symptoms such as
visual field defects, headache, or a decrease of other
pituitary functions may develop because of compression
by the expanding tumour. Elevated levels of prolactin
may cause amenorrhoea, galactorrhoea, and lack of
libido  in  females  and  hypogonadism  in  males.
Acromegaly, caused by a growth hormone producing
tumour, is observed in 3-6% of MEN1 patients. Patients
present with enlarged hands or feet, coarse facial
features or soft-tissue growth. Patients with acromegaly
have an increased risk of developing cardiovascular
disease and malignancy. The diagnosis is confirmed by
determining insulin like growth factor I (IGF-I) levels and
by an oral glucose tolerance test. Pituitary adenomas
can be detected by MR imaging with gadolinium
contrast. If the adenoma has a diameter larger than 10
mm, or if there is visual field loss, a patient is eligible
for transsphenoidal surgery. Dopamine suppresses
prolactin secretion. Hence, the primary treatment of
prolactinomas consists of dopamine receptor agonists
such as bromocriptine, quinagolide or cabergoline. GH
producing cells express the somatostatin receptor.
Somatostatin  is  a repressor  of  GH  secretion,  so
somatostatin analogues are the fist choice of treatment
of acromegaly. If the results are insufficient, surgery
should be considered. ACTH producing adenomas are
removed operatively. 
A Ad dr re en na al l   t tu um mo ou ur rs s
About 20% of MEN1 patients develop adrenal
tumours. These tumours are often detected during
screening  of  the  upper  abdomen.  Like  sporadic
incidentalomas of the adrenals, these tumours usually
do not produce hormones and are mostly benign.
However, when a tumour is larger than 4 cm in
diameter, there is an increased risk of malignancy and
the tumour should be resected [8, 10].
N Ne eu ur ro oe en nd do oc cr ri in ne e   c ca ar rc ci in no oi id d   t tu um mo ou ur rs s
Carcinoid tumours are tumours of neuroendocrine
origin. In MEN1, carcinoid tumours arise from cells
that are derived from the embryonic foregut. Carcinoid
tumours in MEN1 can develop in the thymus (mostly
in males), in the lungs (mostly in females), and in the
stomach or the pancreas. 
Carcinoid tumours in MEN1 usually do not cause
symptoms until at an advanced stage. As these tumours
are capable of infiltrating surrounding tissues and
metastasising, and treatment is very difficult, early
detection of these tumours is important (Fig. 2) [9, 11]. 
Carcinoid tumours produce a vast spectrum of
amines,  peptides  and  prostaglandins.  Carcinoid
tumours in MEN1 do not release serotonin (5HT), but
do produce 5-hydroxytryptophan (5-HTP), the precursor
of serotonin. The 5-HTP is partially converted into
serotonin in the kidneys. Levels of platelet serotonin
and chromogranin A are useful markers. The level of
5-hydroxyindoleacetic acid (5-HIAA) in the 24-hour
urine of MEN1 patients with carcinoid tumours usually
is not elevated. Tumours can be detected using MRI,
SRS or CT. Carcinoid tumours in MEN1 are always
treated surgically. For prevention, when parathyroid
adenomas are removed during a neck dissection, the
thymus could be removed at the same time. 
A Ae et ti io ol lo og gy y   o of f   M ME EN N1 1
MEN1 is caused by inactivating germline mutations
of the MEN1 gene, which is located on chromosome
11q13 [1, 2]. The MEN1 gene is a tumour suppressor
gene. In accordance with Knudson’s ”two-hit theory”,
biallelic inactivation of the MEN1 gene is required for
the development of a tumour cell [12]. Loss of the wild
type allele (loss of heterozygosity) is observed frequently
in MEN1-associated tumours in MEN1 patients. 
Since the discovery of the gene, more than 400
different germline mutations have been identified in
MEN1 families. These mutations are found scattered
throughout the gene. Also in sporadic MEN1-associated
tumours mutations of the MEN1 gene have been found,
which suggests that inactivation of the MEN1 gene
contributes to the development of these tumours. 
No clear genotype-phenotype correlation has been
established. The expression of the disease is variable,
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T Ta ab bl le e   2 2. .   C Cr ri it te er ri ia a   f fo or r   M ME EN N1 1   m mu ut ta at ti io on n   a an na al ly ys si is s   a an nd d   g gu ui id de el li in ne es s   f fo or r   p pe er ri io od di ic ca al l   c cl li in ni ic ca al l   m mo on ni it to or ri in ng g   
C Cr ri it te er ri ia a   f fo or r   m mu ut ta at ti io on n   a an na al ly ys si is s
MEN1 mutation analysis is offered to: 
– MEN1 patients: patients with three of the five major MEN1-associated lesions: parathyroid adenomas, pancreatic islet cell tumours, 
pituitary adenomas, adrenal adenomas, neuroendocrine carcinoid tumours; 
– First degree family members (parents, brothers, sisters, children) of MEN1 patients with a confirmed MEN1 germline mutation,
family members of clinical MEN1 patients without an identified germline mutation or who declined mutation analysis; 
– First degree family members of asymptomatic MEN1 germline mutation carriers; 
– Suspected MEN1 patients: patients with two of the five major lesions, two MEN1-associated tumours within one organ and/or
a MEN1-associated lesion at a young age (<35 years). 
P Pe er ri io od di ic ca al l   c cl li in ni ic ca al l   m mo on ni it to or ri in ng g
MEN1 patients, MEN1 gene germline mutation carriers and suspected MEN1 patients without a confirmed mutation are eligible for periodical 
clinical monitoring. 
This includes: 
From the age of five: biannual clinical examination, laboratory investigation including measurement of ionised calcium, chloride,
phosphate, parathyroid hormone, glucose, insulin, c-peptide, glucagon, gastrin, pancreatic polypeptide, prolactin, insulin like
growth factor 1 (IGF-I), platelet serotonin and chromogranin A. 
From the age of 15: once every two years: 
Magnetic resonance imaging (MRI) of the upper abdomen
MRI of the pituitary with gadolinium contrast
MRI of the mediastinum in males 
even  within  families.  However,  some  MEN1  gene
mutations  seem  to  be  causing  familial  isolated
hyperparathyroidism  or  a variant  MEN1  that  is
characterised by the frequent occurrence of prolactinoma
[13, 14]. Thus, additional genetic events may play a role
in MEN1-associated tumourigenesis. 
The MEN1 gene encodes the menin protein. Menin
is expressed ubiquitously, predominantly in the nucleus.
Menin is a regulator of gene transcription. It has been
reported to interact with several transcription factors such
as JunD and NF-kappaB [15, 16]. Modifications of
histones, the proteins to which DNA is bound, are
important for the function of menin [17, 18]. Recently,
the telomerase (hTERT) gene was identified as a menin
target gene [19]. The ends of chromosomes in a cell,
the telomeres shorten after DNA replication. Eventually,
after several cell divisions, the DNA loses its stability and
the cell is subjected to apoptosis. Telomerase is an
enzyme that maintains the length of the telomeres.
Telomerase is not expressed in normal cells, but it is
active  in  stem  cells  and  tumour  cells.  Menin  is
a suppressor of the expression of telomerase. Possibly,
inactivation of menin could lead to cell immortalisation,
which could allow a cell to develop into a tumour cell. 
Further insight into the mechanisms that underlie
MEN1-associated  tumourigenesis  may  provide
opportunities for new therapeutic strategies. 
M ME EN N1 1   m mu ut ta at ti io on n   a an na al ly ys si is s
Roijers et al found germline mutations in the MEN1
gene in 100% of clinical MEN1 patients by sequence
analysis [3]. Besides MEN1 patients, first degree family
members (parents, brothers, sisters, children) of MEN1
patients, and family members of MEN1 mutation
carriers are eligible for mutation analysis. 
A small percentage of patients with apparently
sporadic MEN1-associated lesions turn out to be carriers
of MEN1 germline mutation. To be able to identify these
patients, without screening the entire group of patients
with apparently sporadic tumours, the above-mentioned
criteria for suspected MEN1 patients were created. In
60% of suspected MEN1 patients a germline mutation
of the MEN1 gene has been found [3]. 
The earliest manifestation of MEN1 reported is
a pituitary adenoma in a five-year-old boy. Therefore,
in principle, mutation analysis could be performed from
the age of five [20]. 
P Pe er ri io od di ic ca al l   c cl li in ni ic ca al l   m mo on ni it to or ri in ng g
MEN1 patients and their family members can be
monitored periodically. The investigation is aimed at
identification of MEN1-associated lesions and includes,
besides the patient’s history and physical examination,
biochemical screening and imaging. The protocol for
periodical clinical monitoring is shown in Table 2. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(1) 6
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C Co on nc cl lu us si io on n
MEN1 is an inherited disorder with a variable
presentation, often at a young age. The initial symptoms
of MEN1-associated lesions may be very general. 
By using stringent criteria MEN1 patients can be
identified efficiently. Mutation analysis enables MEN1
gene mutation carriers to be identified. Gastrinomas
and carcinoid tumours have malignant potential.
Periodical clinical monitoring makes presymptomatic
detection and treatment of MEN1-associated tumours
possible. This will be beneficial for both life expectancy
and quality of life of MEN1 patients. 
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